UT partners with industry to commercialize the discoveries in our labs and bring biologic therapies and innovations to the patient. In the past 10 years, our Discovery to Impact team has executed over 705 option and license agreements.
Aeglea BioTherapeutics is a clinical stage company developing human enzyme therapies for rare metabolic diseases like Arginase 1 Deficiency and Homocystinuria. The company was formed to build a platform of novel human enzyme therapeutics, initially using molecules from UT.
Icosavax is advancing vaccines against severe life-threatening illness, including a candidate for human metapneumovirus (hMPV) using technology from UT.
Vaxxas is commercializing novel vaccination technology which employs a proprietary microprojection patch for delivery to the skin. The company has obtained a license to use the SARS-CoV-2 spike subunit antigen, HexaPro, from UT to enable development of a patch-based vaccine for SARS-CoV-2.
